Last reviewed · How we verify
OSI 7904L
At a glance
| Generic name | OSI 7904L |
|---|---|
| Sponsor | OSI Pharmaceuticals |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- OSI-7904L and Oxaliplatin in Treating Patients With Refractory or Recurrent Advanced Colorectal Cancer (PHASE1)
- Phase I Study of Cisplatin Plus OSI-7904L in Patients With Solid Tumors (PHASE1)
- A Study of OSI-7904L as Treatment in Patients With Head and Neck Cancer Who Have Failed First-Line Therapy (PHASE2)
- Phase II Study of Single Agent OSI-7904L in Patients With Gastric or Gastroesophageal (GEJ) Cancer (PHASE2)
- A Study of OSI-7904L Versus 5-FU/LV as Treatment in Patients With Biliary Tract Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- OSI 7904L CI brief — competitive landscape report
- OSI 7904L updates RSS · CI watch RSS
- OSI Pharmaceuticals portfolio CI